new BindingDB logo
myBDB logout

139 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28686445 39 Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.EBI Sun Yat-Sen University
28406621 65 Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.EBI Dart Neuroscience LLC
28165743 37 Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.EBI Dart Neuroscience LLC
28196708 26 Design, synthesis and biological evaluation of 2,4-disubstituted oxazole derivatives as potential PDE4 inhibitors.EBI South China Agricultural University
8230117 4 The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.EBI SmithKline Beecham Pharmaceuticals
1479586 8 New bronchodilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones.EBI Kyowa Hakko Kogyo Co., Ltd.
1656043 4 New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.EBI Universidad de Navarra
2153209 6 Synthesis and cardiotonic activity of novel biimidazoles.EBI Merrell Dow Research Institute
2738882 9 Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.EBI Lilly Research Laboratories
2846840 20 Inhibitors of cyclic AMP phosphodiesterase. 4. Synthesis and evaluation of potential prodrugs of lixazinone (N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro-2- oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide, RS-82856).EBI Syntex Research
3039132 26 Cardiotonic agents. 2. (Imidazolyl)aroylimidazolones, highly potent and selective positive inotropic agents.EBI TBA
3965705 10 2-(beta-Arylethylamino)- and 4-(beta-arylethylamino)quinazolines as phosphodiesterase inhibitors.EBI TBA
14980691 15 Orally active PDE4 inhibitors with therapeutic potential.EBI Minase Research Institute
14684291 14 New orally active PDE4 inhibitors with therapeutic potential.EBI Minase Research Institute
14684329 27 Highly potent PDE4 inhibitors with therapeutic potential.EBI Minase Research Institute
12668000 29 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors.EBI National Institute of Pharmaceutical Education and Research (NIPER)
12852946 69 Comparative molecular field analysis (CoMFA) of phthalazine derivatives as phosphodiesterase IV inhibitors.EBI National Institute of Pharmaceutical Education and Research
12824031 26 Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.EBI Tanabe Seiyaku Co., Ltd.
11814830 26 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.EBI Celltech R& D
12039576 17 Synthesis and profile of SCH351591, a novel PDE4 inhibitor.EBI Schering-Plough Corporation
12039575 18 8-Methoxyquinolines as PDE4 inhibitors.EBI Schering-Plough Corporation
12039574 16 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.EBI Celltech R&D
11738561 34 Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.EBI Zambon Group
11140727 31 Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.EBI Zambon Group
11128646 69 Synthesis and biological evaluation of 2,5-dihydropyrazol.EBI Rhône-Poulenc Rorer
11012037 25 The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.EBI Zambon Group
10999488 34 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.EBI Celltech-Chiroscience Ltd
10636238 71 Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.EBI Institut de Recherche Jouveinal-Parke Davis
9871607 32 Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.EBI Rhône-Poulenc Rorer
9871693 46 Quaternary substituted PDE IV inhibitors II: the synthesis and in vitro evaluation of a novel series of gamma-lactams.EBI Rh£ne-Poulenc Rorer Central Research
9873675 44 Orally active indole N-oxide PDE4 inhibitors.EBI Rh£ne-Poulenc Rorer Central Research
9873649 25 PDE4 inhibitors: new xanthine analogues.EBI Chiroscience Ltd
9871649 26 Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.EBI Rh£ne-Poulenc Rorer Central Research
9873600 14 Thalidomide analogs and PDE4 inhibition.EBI Celgene Corporation
9873613 15 2-Substituted-4-methoxybenzimidazole-based PDE4 inhibitors.EBI Rh£ne-Poulenc Rorer
9873593 15 Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.EBI Chiroscience Ltd
9873449 49 The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.EBI Rh£ne-Poulenc Rorer Central Research
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
27301679 21 Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.EBI Takeda Pharmaceutical Company Limited
26978121 20 Discovery and modelling studies of natural ingredients from Gaultheria yunnanensis (FRANCH.) against phosphodiesterase-4.EBI Sun Yat-Sen University
26976215 5 Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.EBI Vanderbilt University School of Medicine
26935942 41 Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.EBI Mercachem
26681511 33 Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.EBI Sanofi Research Center
26526739 35 Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.EBI Southern Medical University
26288683 43 Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.EBI Bristol-Myers Squibb R&D
26288344 15 Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).EBI Novartis Institutes for Biomedical Research
25936260 8 Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.EBI University of Genoa
26005524 147 Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.EBI Merck Research Laboratories
25815146 29 Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.EBI Janssen Pharmaceutica N.V.
25736998 37 Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.EBI Merck Serono Research& Development
25126889 10 Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.EBI University of Genoa
24998378 62 Discovery of triazines as selective PDE4B versus PDE4D inhibitors.EBI Northern Illinois University
24984230 22 Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis.EBI LEO Pharma A/S
25075977 12 Prostaglandin Derivatives: Nonaromatic Phosphodiesterase-4 Inhibitors from the Soft Coral Sarcophyton ehrenbergi.EBI Sun Yat-sen University
25456383 113 Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.EBI TBA
25264825 54 Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.EBI Centro de Investigaciones Biol�gicas (CSIC)
25221665 33 Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.EBI Janssen Pharmaceutica NV
25149511 34 Novel Roflumilast analogs as soft PDE4 inhibitors.EBI Amakem N.V.
24785301 83 Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.EBI AstraZeneca
24597921 14 Prenylated coumarins: natural phosphodiesterase-4 inhibitors from Toddalia asiatica.EBI Sun Yat-sen University
9873708 16 N-arylrolipram derivatives as potent and selective PDE4 inhibitors.EBI Novartis Horsham Research Center
23294698 8 Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.EBI University of Hyderabad Campus
23149228 60 Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.EBI Amgen Inc.
22985069 18 Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.EBI Sun Yat-Sen University
22963052 38 Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.EBI VU University Amsterdam
22944118 27 Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model.EBI Glenmark Pharmaceuticals Limited
22891752 18 Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.EBI Universidade Federal do Rio de Janeiro
22889281 36 Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.EBI Novartis Institutes for Biomedical Research
22385507 20 Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.EBI Instituto de Qu£mica M£dica (CSIC)
22483586 10 Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.EBI Sun Yat-Sen University
22401864 61 Discovery of oxazole-based PDE4 inhibitors with picomolar potency.EBI Merck Research Laboratories
20188577 23 In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.EBI King's College London
19014888 52 Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.EBI Human BioMolecular Research Institute
18686943 28 Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.EBI Matrix Laboratories Limited
17337182 23 Potent and selective xanthine-based inhibitors of phosphodiesterase 5.EBI Novartis Institutes of Biomedical Research
17228876 36 SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.EBI Pfizer Global Research and Development
16168647 80 Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.EBI Merck Frosst Centre for Therapeutic Research
15887951 29 The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.EBI Monash University (Parkville Campus)
11405657 123 Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.EBI Tanabe Seiyaku Co., Ltd.
10691693 64 Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.EBI Novartis Pharma AG
10090791 77 Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.EBI Tanabe Seiyaku Company, Ltd.
8388468 37 Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.EBI SmithKline Beecham Pharmaceuticals
12824030 67 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.EBI Tanabe Seiyaku Co., Ltd.
11755362 24 Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.EBI Novartis Pharma AG
22030030 5 Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.EBI Monash University (Parkville campus)
21871695 46 Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.EBI Rhône-Poulenc Rorer
20933411 69 Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.EBI Merck Frosst Centre for Therapeutic Research
19447034 76 Discovery of selective PDE4B inhibitors.EBI Asahi Kasei Pharma Corporation
21602043 50 Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.EBI H. Lundbeck A/S
21087867 30 Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.EBI Universit£ di Sassari
20825218 69 Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.EBI Rhône-Poulenc Rorer
20813948 63 Spiroindolones, a potent compound class for the treatment of malaria.EBI Swiss Tropical and Public Health Institute
20709547 69 The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.EBI Merck Frosst Centre for Therapeutic Research
20202838 62 Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.EBI Pfizer Global Research and Development
19361990 7 Surface plasmon resonance-based detection of ladder-shaped polyethers by inhibition detection method.EBI Osaka University
20053559 55 Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.EBI Korea Research Institute of Chemical Technology
20196613 32 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI Pfizer Global Research and Development
19744860 19 Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors.EBI Kyoto 601-8550
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19827751 21 New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms.EBI University of Genoa
 5 The Gif system as a tool in medicinal chemistry: The oxidation of Sch 57726 under GoAggIII conditionsEBI TBA
19339180 69 The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI Pfizer Global Research and Development
19049349 107 Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.EBI Georgia State University
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
16516471 114 Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.EBI Merck Frosst Center for Therapeutic Research
16275071 26 A new chemical tool for exploring the physiological function of the PDE2 isozyme.EBI Pfizer, Inc.
16263279 37 A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.EBI Pfizer, Inc.
15324877 90 Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.EBI Pfizer Global Research and Development
15324876 94 Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.EBI Pfizer Global Research and Development
15324874 169 Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.EBI Pfizer Global Research and Development
15149695 24 New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.EBI Pfizer Global Research and Development
14521415 44 The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.EBI Centre de Recherches
11958981 25 Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.EBI BAYER AG
10937713 186 Solid-phase synthesis of an arylsulfone hydroxamate library.EBI Rhone Poulenc Rorer
10197972 133 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.EBI Tanabe Seiyaku Company, Ltd.
9873643 75 Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.EBI Novartis Pharma AG
9873594 44 Aryl sulfonamides as selective PDE4 inhibitors.EBI Chiroscience Ltd
9464356 24 Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.EBI Pfizer Inc.
8496906 127 Bronchodilator activity of xanthine derivatives substituted with functional groups at the 1- or 7-position.EBI Hokuriku University
2544722 94 Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues.EBI Centre de Neurochimie du CNRS
28800229 2 Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors.EBI IOTA Pharmaceuticals
1331453 106 Effects of alkyl substitutions of xanthine skeleton on bronchodilation.EBI Hokuriku University
10087018 11 Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.BDB University of Rochester
9349523 22 Cloning and expression of a human serotonin 5-HT4 receptor cDNA.BDB Janssen Research Foundation
17629487 20 Alpha-substituted N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists.BDB Seoul National University
15632123 9 A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo.BDB Genentech
7684450 26 Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a BDB Upjohn